CA3097359A1 - Glucose-responsive insulin - Google Patents

Glucose-responsive insulin Download PDF

Info

Publication number
CA3097359A1
CA3097359A1 CA3097359A CA3097359A CA3097359A1 CA 3097359 A1 CA3097359 A1 CA 3097359A1 CA 3097359 A CA3097359 A CA 3097359A CA 3097359 A CA3097359 A CA 3097359A CA 3097359 A1 CA3097359 A1 CA 3097359A1
Authority
CA
Canada
Prior art keywords
peptide
insulin
chain
seq
chain peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3097359A
Other languages
English (en)
French (fr)
Inventor
Danny Hung-Chieh Chou
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Utah Research Foundation Inc
Original Assignee
University of Utah Research Foundation Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Utah Research Foundation Inc filed Critical University of Utah Research Foundation Inc
Publication of CA3097359A1 publication Critical patent/CA3097359A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Zoology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CA3097359A 2018-04-16 2019-04-15 Glucose-responsive insulin Pending CA3097359A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862658372P 2018-04-16 2018-04-16
US62/658,372 2018-04-16
PCT/US2019/027484 WO2019204206A1 (en) 2018-04-16 2019-04-15 Glucose-responsive insulin

Publications (1)

Publication Number Publication Date
CA3097359A1 true CA3097359A1 (en) 2019-10-24

Family

ID=68239869

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3097359A Pending CA3097359A1 (en) 2018-04-16 2019-04-15 Glucose-responsive insulin

Country Status (8)

Country Link
US (1) US20210214412A1 (enExample)
EP (1) EP3781147A4 (enExample)
JP (1) JP2021521230A (enExample)
KR (1) KR20210005630A (enExample)
CN (1) CN112423741A (enExample)
AU (1) AU2019255611A1 (enExample)
CA (1) CA3097359A1 (enExample)
WO (1) WO2019204206A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11052133B2 (en) 2015-05-06 2021-07-06 Protomer Technologies, Inc. Glucose responsive insulins
EP3939605A1 (en) 2016-12-09 2022-01-19 Akston Biosciences Corporation Insulin-fc fusions and methods of use
MA50552A (fr) 2017-11-09 2020-09-16 Novo Nordisk As Dérivés de liaison à l'albumine sensibles au glucose
HUE062719T2 (hu) 2018-06-29 2023-11-28 Akston Biosciences Corp Ultra-hosszú hatású inzulin-FC fúziós fehérjék és az alkalmazási eljárások
US11267862B2 (en) 2018-06-29 2022-03-08 Akston Biosciences Corporation Ultra-long acting insulin-Fc fusion proteins and methods of use
TWI717245B (zh) * 2019-03-29 2021-01-21 丹麥商諾佛 儂迪克股份有限公司 葡萄糖敏感型胰島素衍生物
WO2021022116A1 (en) * 2019-07-31 2021-02-04 Thermalin Inc. Insulin analogues with glucose regulated conformational switch
KR102865175B1 (ko) 2019-12-19 2025-09-30 악스톤 바이오사이언시스 코퍼레이션 초-장기 작용 인슐린-fc 융합 단백질 및 사용 방법
US11186623B2 (en) 2019-12-24 2021-11-30 Akston Bioscience Corporation Ultra-long acting insulin-Fc fusion proteins and methods of use
KR20220161422A (ko) * 2020-03-31 2022-12-06 프로토머 테크놀로지스 인크. 비시날 디올에 대한 선택적인 반응을 위한 접합체
LT3972987T (lt) 2020-04-10 2023-09-25 Akston Biosciences Corporation Antigenui specifinė imunoterapija, skirta sulietiems covid-19 baltymams ir naudojimo būdai
US11192930B2 (en) 2020-04-10 2021-12-07 Askton Bioscences Corporation Ultra-long acting insulin-Fc fusion protein and methods of use
US11198719B2 (en) 2020-04-29 2021-12-14 Akston Biosciences Corporation Ultra-long acting insulin-Fc fusion protein and methods of use
KR20230110505A (ko) * 2020-11-19 2023-07-24 프로토머 테크놀로지스 인크. 방향족 붕소-함유 화합물 및 인슐린 유사체
US11667689B2 (en) 2021-07-23 2023-06-06 Akston Biosciences Corporation Insulin-Fc fusion proteins and methods of use to treat cancer
WO2023156849A2 (en) * 2022-02-17 2023-08-24 Revolo Biotherapeutics Limited Method of producing peptide derived from chaperonin 60.1
PE20251287A1 (es) 2022-05-18 2025-05-14 Protomer Tech Inc Compuestos aromaticos que contienen boro y analogos de insulina relacionados
WO2025117822A1 (en) * 2023-11-28 2025-06-05 University Of Notre Dame Du Lac Glucose-triggered gelation of supramolecular peptide nanocoils with glucose-binding motifs

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6070100A (ja) * 1983-09-26 1985-04-20 Wako Pure Chem Ind Ltd 新規ヒト型インシュリン誘導体，その製法，及びヒト型インシュリンの製造法
DE3837825A1 (de) * 1988-11-08 1990-05-10 Hoechst Ag Neue insulinderivate, ihre verwendung und eine sie enthaltende pharmazeutische zubereitung
US7317000B2 (en) * 2001-12-02 2008-01-08 Novo Nordisk A/S Glucose-dependent insulins
EP1453860A2 (en) * 2001-12-02 2004-09-08 Novo Nordisk A/S Novel glucose-dependant insulins
US7928186B2 (en) * 2006-08-02 2011-04-19 Phoenix Pharmaceuticals, Inc. Cell permeable bioactive peptide conjugates
BR112012020481A2 (pt) * 2010-02-22 2017-01-10 Univ Case Western Reserve método para tratar um paciente, o método compreendendo administrar uma formulação farmacêutica contendo uma quantidade fisiologicamente efetiva de um análogo de insulina ou um sal fisiologicamente.
UA113626C2 (xx) * 2011-06-02 2017-02-27 Композиція для лікування діабету, що містить кон'югат інсуліну тривалої дії та кон'югат інсулінотропного пептиду тривалої дії
US20160031962A1 (en) * 2012-04-20 2016-02-04 Kleomenis K. Barlos Solid phase peptide synthesis of insulin using side chain achored lysine
US9867869B2 (en) * 2012-12-12 2018-01-16 Massachusetts Institute Of Technology Insulin derivatives for diabetes treatment
US11052133B2 (en) * 2015-05-06 2021-07-06 Protomer Technologies, Inc. Glucose responsive insulins

Also Published As

Publication number Publication date
EP3781147A1 (en) 2021-02-24
AU2019255611A1 (en) 2020-11-12
KR20210005630A (ko) 2021-01-14
CN112423741A (zh) 2021-02-26
JP2021521230A (ja) 2021-08-26
EP3781147A4 (en) 2022-04-20
WO2019204206A1 (en) 2019-10-24
US20210214412A1 (en) 2021-07-15

Similar Documents

Publication Publication Date Title
US20210214412A1 (en) Glucose-responsive insulin
TWI910174B (zh) Ｇｌｐ-１和ｇｉｐ受體雙重激動劑化合物及其應用
TWI792596B (zh) 新穎脂肪酸及其於共軛至生物分子之用途
ES2271723T3 (es) Utilizacion de derivados de tiazolidina como agentes de antihiperglicemicos.
EP4442700A1 (en) Pharmaceutical composition of glp-1 and gip receptor dual agonist and use thereof
US20160235855A1 (en) Stable aqueous parenteral pharmaceutical compositions of insulinotropic peptides
US11155577B2 (en) Thiol-ene based peptide stapling and uses thereof
TW202039438A (zh) 胰島素接合物
TWI672315B (zh) 醯化之胰島素化合物
US20240041982A1 (en) Extended release hydrogel conjugates of c-natriuretic peptides
US20210177981A1 (en) Conjugate based systems for controlled insulin delivery
JP2019519478A (ja) ペプチド−オリゴ尿素フォルダマー化合物及びそれらの使用方法
TW202409070A (zh) 芳族含硼化合物及相關胰島素類似物
CN106554404A (zh) 一种艾塞那肽修饰物及其用途
JP6005732B2 (ja) 非ペプチド性重合体−インスリン多量体及びその製造方法
WO2017212494A1 (en) Long-acting oxyntomodulin formulation and methods of producing and administering same
JP2008531482A (ja) Ｃ末端がｐｅｇ化された成長ホルモン
EP4357358A1 (en) Glucagon analog and medical use thereof
CN107365375B (zh) 一种对glp-1受体具有高亲和性的多肽化合物及其制备方法和应用
US20250186538A1 (en) Bivalirudin compounds
CN116917297A (zh) 芳香族含硼化合物和胰岛素类似物
HK40069563B (en) Dual-agonist compound for both glp-1 and gip receptors and application thereof
BR112019021668B1 (pt) Composto acilado de insulina, uso do mesmo, e composição farmacêutica que o compreende
JPH01102100A (ja) 糖鎖をもつヒト・インターフェロンβ

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220927

B12 Application deemed to be withdrawn, abandoned or lapsed

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B12-B303 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO AN EXAMINER'S REQUISITION

Effective date: 20240725